{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:09Z","timestamp":1792265049697,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":1118,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1093\/annonc\/mdw417","type":"journal-article","created":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T00:19:30Z","timestamp":1474071570000},"page":"2288-2294","source":"Crossref","is-referenced-by-count":123,"title":["Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy"],"prefix":"10.1016","volume":"27","author":[{"given":"K.A.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.A.","family":"Abuodeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.I.","family":"Echevarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Arrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Stallworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.O.","family":"Naghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.G.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sarangkasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.S.","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sahebjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.I.","family":"Khushalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.B.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Etame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Caudell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw417_bb0010","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw417_bb0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","article-title":"Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients","volume":"77","author":"Sperduto","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdw417_bb0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw417_bb0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw417_bb0030","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw417_bb0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw417_bb0040","first-page":"965","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open\u2010label, single\u2010arm, phase 2, multicenter study","volume":"26","author":"Kefford GMR","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1093\/annonc\/mdw417_bb0045","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdw417_bb0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","article-title":"Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery","volume":"23","author":"Mathew","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdw417_bb0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-014-1685-x","article-title":"LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases","volume":"122","author":"Ahmed","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdw417_bb0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw417_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw417_bb0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CMR.0000000000000250","article-title":"Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdw417_bb0075","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw417_bb0080","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/0959-8049(94)00297-I","article-title":"A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma","volume":"30A","author":"Chang","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw417_bb0085","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","article-title":"Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study","volume":"22","author":"Agarwala","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw417_bb0090","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw417_bb0095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw417_bb0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw417_bb0105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/his.12537","article-title":"Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases","volume":"66","author":"Berghoff","year":"2015","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdw417_bb0110","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/annonc\/mdu266","article-title":"On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases","volume":"25","author":"Gaudy-Marqueste","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw417_bb0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11060-013-1127-1","article-title":"Vemurafenib and radiation therapy in melanoma brain metastases","volume":"113","author":"Narayana","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdw417_bb0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1667\/RR13712.1","article-title":"Effects of high-dose microbeam irradiation on tumor microvascular function and angiogenesis","volume":"183","author":"Fontanella","year":"2015","journal-title":"Radiat Res"},{"key":"10.1093\/annonc\/mdw417_bb0125","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0360-3016(01)02772-9","article-title":"Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery","volume":"52","author":"Yu","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/12\/2288\/13789487\/mdw417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:02:59Z","timestamp":1624694579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0923753419365408"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw417","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}